Severity of Lesions Assessed by FFR in Coronary Disease: Is It Associated with Major Events?

severity of lesions ffrIn patients with coronary disease, the prognosis depends on the extent and reversibility of myocardial ischemia. Whether the outcome also depends on the severity of stenosis as determined by fractional flow reserve (FFR) has not been studied yet.

 

This study investigates the relationship between fractional flow reserve values and vessel-related events. Major adverse cardiovascular events (MACE) at 2 years were prospectively studied in 607 patients in whom all stenoses were assessed by FFR and who received medical therapy only.

 

Moreover, logistic regression models were used to calculate the decrease in the risk per 0.05 increase in FFR values.

 

Events were present for 272 (26.5%) of 1029 lesions. Lesions with stenosis diameter ≥70% were more often present in the group experiencing events (p <0.01).

 

The mean fractional flow reserve value was significantly lower in the group experiencing events than in the group with no events (0.68 vs. 0.80; p <0.01).

 

The cumulative incidence of MACE significantly increases with increasing FFR quartiles.

 

The average decrease in MACE per 0.05 increase in FFR was statistically significant, even after adjustment for all clinical and angiographic variables. The strongest increase in adverse events occurred for FFR values between 0.80 and 0.60. In a multivariate analysis, FFR was significantly associated with events at 2 years

 

Conclusion

In patients with stable coronary disease, functional severity of a lesion as assessed by fractional flow reserve is independently associated with major cardiovascular events.

 

Original title: A Prospective Natural History Study of Coronary Atherosclerosis Using Fractional Flow Reserve.

Reference: Emanuele Barbato et al. J Am Coll Cardiol. 2016;68(21):2247-2255.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

ACC 2026 | CHIP-BCIS3: Impella use as support in high-risk complex PCI

The use of percutaneous ventricular support during high-risk complex PCI has been proposed as a strategy to prevent hemodynamic deterioration in patients with severe...

ACC 2026 | ORBITA-CTO: PCI in chronic total occlusions and stable angina — the randomized trial we were missing?

Percutaneous coronary intervention (PCI) for chronic total occlusions (CTO) remains a topic of ongoing debate in stable angina, with persistent uncertainty regarding its role...

ACC 2026 | FAST III: vFFR vs FFR in physiology-guided revascularization of intermediate coronary lesions

Physiological assessment of intermediate coronary lesions remains a cornerstone in decision-making for coronary revascularization. Although FFR continues to be one of the guideline-recommended references,...

ACC 2026 | STEMI-Door To Unload: Unloading with Impella before PCI did not reduce infarct size in anterior STEMI

Anterior ST-segment elevation myocardial infarction (STEMI) remains associated with a high incidence of heart failure and mortality, even in the era of early reperfusion....

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC 2026 | CHIP-BCIS3: Impella use as support in high-risk complex PCI

The use of percutaneous ventricular support during high-risk complex PCI has been proposed as a strategy to prevent hemodynamic deterioration in patients with severe...

ACC 2026 | ORBITA-CTO: PCI in chronic total occlusions and stable angina — the randomized trial we were missing?

Percutaneous coronary intervention (PCI) for chronic total occlusions (CTO) remains a topic of ongoing debate in stable angina, with persistent uncertainty regarding its role...

ACC 2026 | FAST III: vFFR vs FFR in physiology-guided revascularization of intermediate coronary lesions

Physiological assessment of intermediate coronary lesions remains a cornerstone in decision-making for coronary revascularization. Although FFR continues to be one of the guideline-recommended references,...